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Abstract: PURPOSE: To externally validate recently published prostate cancer risk calculators (PCa-
RCs) incorporating multiparametric magnetic resonance imaging (mpMRI) for the prediction of clinically
significant prostate cancer (csPCa) and compare their performance to mpMRI-naïve PCa-RCs. MATE-
RIAL AND METHODS: Men without previous PCa diagnosis undergoing transperineal template satu-
ration prostate biopsy with fusion-guided targeted biopsy between 11/2014 and 03/2018 in our academic
tertiary referral center were identified. Any Gleason pattern ฀4 was defined to be csPCa. Predictors
(age, PSA, DRE, prostate volume, family history, previous prostate biopsy and highest region of inter-
est according to PIRADS) were retrospectively collected. Four mpMRI-PCa-RCs and two mpMRI-naïve
PCa-RCs were evaluated for their discrimination, calibration and clinical net benefit using a ROC analysis,
calibration plots and a decision curve analysis, respectively. RESULTS: Out of 468 men, 193 (41%) were
diagnosed with csPCa. Three mpMRI-PCa-RCs showed similar discrimination with area-underneath-
the-receiver-operating-characteristic-curves (AUC) from 0.83 to 0.85, which was significantly higher than
the other PCa-RCs (AUCs: 0.69-0.74). Calibration-in-the-large showed minimal deviation from the true
amount of csPCa by 2% for two mpMRI-PCa-RCs, while the other PCa-RCs showed worse calibration
(11-27%). A clinical net benefit could only be observed for three mpMRI-PCa-RCs at biopsy thresh-
olds ฀15%, while none of the six investigated PCa-RCs demonstrated clinical utility against a biopsy
all strategy at thresholds <15%. CONCLUSIONS: Performance of the mpMRI-PCa-RCs varies, but
they generally outperform mpMRI-naïve PCa-RCs in regard to discrimination, calibration and clinical
usefulness. External validation in other biopsy settings is highly encouraged.
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 41 
Abstract 42 
Purpose: To externally validate recently published prostate cancer risk calculators (PCa-RCs) 43 
incorporating multiparametric magnetic resonance imaging (mpMRI) for the prediction of clinically 44 
significant prostate cancer (csPCa) and compare their performance to mpMRI-naïve PCa-RCs. 45 
 46 
Material and Methods: Men without previous PCa diagnosis undergoing transperineal template 47 
saturation prostate biopsy with fusion-guided targeted biopsy between 11/2014 and 03/2018 in our 48 
academic tertiary referral center were identified. Any Gleason pattern ≥4 was defined to be csPCa. 49 
Predictors (age, PSA, DRE, prostate volume, family history, previous prostate biopsy and highest 50 
region of interest according to PIRADS) were retrospectively collected. Four mpMRI-PCa-RCs and two 51 
mpMRI-naïve PCa-RCs were evaluated for their discrimination, calibration and clinical net benefit 52 
using a ROC analysis, calibration plots and a decision curve analysis, respectively. 53 
 54 
Results: Out of 468 men, 193 (41%) were diagnosed with csPCa. Three mpMRI-PCa-RCs showed 55 
similar discrimination with area-underneath-the-receiver-operating-characteristic-curves (AUC) from 56 
0.83 to 0.85, which was significantly higher than the other PCa-RCs (AUCs: 0.69-0.74). Calibration-in-57 
the-large showed minimal deviation from the true amount of csPCa by 2% for two mpMRI-PCa-RCs, 58 
while the other PCa-RCs showed worse calibration (11-27%). A clinical net benefit could only be 59 
observed for three mpMRI-PCa-RCs at biopsy thresholds ≥15%, while none of the six investigated 60 
PCa-RCs demonstrated clinical utility against a biopsy all strategy at thresholds <15%. 61 
 62 
Conclusions: Performance of the mpMRI-PCa-RCs varies, but they generally outperform mpMRI-naïve 63 
PCa-RCs in regard to discrimination, calibration and clinical usefulness. External validation in other 64 




Prostate-specific antigen (PSA) screening leads to more diagnoses of localized instead of advanced 69 
prostate cancer (PCa)
1
, but has also resulted in overdiagnosis of clinically insignificant PCa
2
. Instead 70 
of relying on PSA and digital rectal examination (DRE) as the sole criteria to biopsy men, use of 71 
multivariable PCa risk calculators (PCa-RCs) provide possibly more accurate predictions for PCa
3
 and 72 
may hereby reduce the number of negative prostate biopsies and overdiagnosis
4
. Multiparametric 73 
magnetic resonance imaging (mpMRI) has been shown to reduce the number of unnecessary 74 
prostate biopsies, when used as a triage test
5
. Furthermore, mpMRI has recently been incorporated 75 
into PCa-RCs to enhance their predictive ability for clinically significant prostate cancer (csPCa)
6–9
. It 76 
has been shown that certain mpMRI-naïve PCa-RCs perform worse in external validation studies, 77 
than would have been anticipated from their original reports
10,11
. Hence, we externally validated four 78 
novel PCa-RCs incorporating mpMRI
6–9
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Material and Methods 82 
 83 
Study design and setting 84 
All men who underwent mpMRI and transperineal template saturation prostate biopsy with 85 
additional fusion-guided targeted biopsy for suspicion of csPCa from 11/2014–03/2018 in an 86 
academic tertiary referral center were considered for this study. Transrectal ultrasound–mpMRI 87 
fusion and virtual needle placement were done using the BiopSEE® software (MedCom, Darmstadt, 88 
Germany) for systematic biopsy as reported previously
14
. Additional fusion-guided targeted biopsies 89 
(2-4 cores) were performed for each region of interest (ROI) classified as grade ≥3 according to the 90 
Prostate Imaging Reporting and Data System (PIRADS) version 2. A specialized uro-pathologist 91 
assessed each core separately. Any Gleason pattern ≥4 was defined to be csPCa. 92 
Patients either underwent mpMRI at our institution (including triplanar T2- and diffusion-weighted 93 
and dynamic contrast-enhanced sequences) or were referred to our institution after having mpMRI 94 
performed externally. In case Likert scale or PIRADSv1 was used, internal reassessment according to 95 
PIRADSv2 guidelines
15
 was done by specialized uro-radiologists. Cases with qualitative insufficiently 96 
performed MRIs were excluded. Predictors (age, PSA, DRE, prostate volume, family history, previous 97 
biopsy and highest ROI-grade on mpMRI) were retrospectively retrieved from electronic medical 98 
records. The study was approved by the local ethics committee. 99 
 100 
Analysis 101 
We investigated four PCa-RCs incorporating mpMRI (Radtke et al.
9
, van Leeuwen et al.
6





) and two conventional mpMRI-naïve PCa-RCs (ERSPC-RC
12
 and PBCG-103 
RC
13
). Specifics of the corresponding studies are outlined in the Supplementary Table. For three PCa-104 
RCs
6,7,9
 predictions were calculated based on published logistic regression models. For the other PCa-105 





.  Although family history information was missing for almost half of our 107 
cohort, predictions could still be calculated for all patients as this predictor is only inquired by the 108 
PBCG-RC as an optional input variable. For other marginally missing values such as highest grade 109 
according to PIRADS and DRE no missingness assumptions were made (complete case analysis). 110 
We performed two sensitivity analyses: First, we investigated the effect of missing family history 111 
information on the performance of the PBCG-RC by repeating the analysis among patients with 112 
complete and among an imputed dataset. Second, the performance of the PCa-RC of Mehralivand et 113 
al. was reanalyzed in a cohort restricted to cases with positive mpMRI (PIRADS grade ≥3) to account 114 
for the peculiar low amount of PIRADS grade <3 (8.1%) of its development cohort. In addition, we 115 
evaluated potential performance improvements by recalibration as described by Strobl and 116 
colleagues
16,17
. For this, two thirds of our cohort (training cohort) was used to update the models 117 
while the remaining third was used as a validation cohort. 118 
For each PCa-RC we assessed discrimination, calibration and clinical usefulness. Discrimination was 119 
evaluated by area-under-the-receiver-operating-characteristics-curves (AUC). Calibration-in-the-large 120 
was assessed by comparing the predicted proportion of csPCa from each PCa-RC to the proportion 121 
observed in our cohort. We further investigated model calibration both numerically (intercept and 122 
slope) and visually (calibration plot). Clinical usefulness was assessed by a decision curve analysis 123 
(DCA)
18
. All analyses were performed in R 3.4.4 (R Foundation for Statistical Computing, Vienna, 124 




 and rms (Calibration plots)
21
 packages. 125 
The DCA was implemented by the published code of Vickers et al.
18
 126 
Results  127 
A total of 935 men were considered for this study. After excluding 401 patients with previously 128 
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individuals with missing DRE information, 468 men were left for analysis. Table 1 summarizes the 130 
cohorts’ clinicopathological characteristics and biopsy results. In our cohort, median age was 64.5 131 
years (interquartile range [IQR]: 59-68.9), median PSA was 6.6 ng/ml (IQR: 4.5-9.9) and median 132 
prostate volume was 48.9ml (IQR: 36-63.7). There were 145 (31%) men who had at least one 133 
previous negative prostate biopsy. In 87 (18.5%) cases no ROI was seen on mpMRI. Highest ROI was 134 
graded to be PIRADS 2, 3, 4 and 5 in 68 (14.5%), 94 (20%), 162 (34.6%) and 57 (12.2%) cases, 135 
respectively. Median systematic biopsy core number was 40 (IQR: 39-42) and median number of 136 
targeted biopsy cores per ROI was 3 (IQR: 2-3). Gleason Score 3+3=6 PCa was found in 55 (11.8%) 137 
patients and csPCa was diagnosed in 193 (41.2%) Patients. 138 
AUCs with corresponding 95%-confidence intervals (95%-CI) for PCa-RCs under evaluation are shown 139 
in Figure 1. The AUCs of three mpMRI-PCa-RCs were comparable (mpMRI-ERSPC-RC: AUC of 0.85 140 
[95%-CI: 0.82-0.89]; Mehralivand et al.: 0.84 [95%-CI: 0.80-0.87] and van Leeuwen et al.: 0.83 [95%-141 
CI: 0.80-0.87]), but were considerably higher compared to the mpMRI-PCa-RC of Radtke et al. (AUC 142 
of 0.73 [95%-CI: 0.69-0.78]) and the mpMRI-naïve PCa-RCs (ERSPC-RC: AUC of 0.74 [95%-CI: 0.69-143 
0.79]; PBCG-RC: AUC of 0.69 [95%-CI: 0.65-0.74]). 144 
Calibration-in-the-large and calibration plots for each PCa-RC (including intercept and slope 145 
indicating miscalibration and overfitting, respectively) are visualized in Figures 2 and 3. Calibration-in-146 
the-large of the mpMRI-PCa-RCs of Radtke et al. (+2%) and van Leeuwen et al. (-2%) showed minimal 147 
deviation from the observed proportion of 41% csPCa in our cohort, while the mpMRI-ERSPC-RC 148 
(deviation of -14%) and the PBCG-RC (deviation of -11%) exhibited intermediate miscalibration. The 149 
mpMRI-PCa-RC of Mehralivand et al. and the mpMRI-naïve ERSPC-RC yielded large deviations of 150 
+27% and -29%, respectively. When it comes to overfitting, the mpMRI-PCa-RCs of Radkte et al. and 151 
van Leeuwen et al. produce too extreme predictions as reflected by their calibration slopes 152 
considerably smaller than 1 in comparison to the other PCa-RCs. 153 
Clinical usefulness was evaluated using DCA (Figure 4). In a scenario where missing 10% of csPCa is 154 
acceptable, application of any PCa-RCs under evaluation even showed to be clinically harmful 155 
compared to the strategy to biopsy all. For a more commonly used clinical threshold probability of 156 
15% – at which the downside of 5.6 unnecessary prostate biopsies is equated to missing one csPCa – 157 
use of three mpMRI-PCa-RCs (mpMRI-ERSPC-RC, the one from van Leeuwen et al. and from 158 
Mehralivand et al.) exhibited a clinical net benefit. At this threshold the use of the mpMRI-ERSPC-RC 159 
and the PCa-RC by van Leeuwen et al. would omit 84 and 67 per 1000 prostate biopsies, respectively, 160 
without missing one case of csPCa. Use of the other three PCa-RCs under evaluation exhibited net 161 
harm in this scenario. 162 
To explore whether the worse performance of the mpMRI-naïve PBCG-RC is potentially driven by the 163 
high proportion of missing family history information, we performed a sensitivity analysis involving 164 
only patients with available family history (n=278) and a multiple imputed dataset (n=468). Neither 165 
the discrimination (AUCavailable family history: 0.67, AUCimputed: 0.70) nor the calibration (interceptavailable family 166 
history: 0.35, interceptimputed: 0.40, slopenon-missing family history: 0.70, slopeimputed: 0.78) were substantially 167 
improved. We further hypothesized that the mpMRI-PCa-RC of Mehralivand et al. would perform 168 
better for patients with a PIRADS grade ≥3, in accordance with its development cohort characteristics 169 
(92% with PIRADS grade ≥3). Our sensitivity analysis with mpMRI positive patients only (PIRADS ≥3; 170 
n=313) showed no improvement of discrimination (AUC of 0.81 [95%-CI: 0.76-0.85]), but an 171 
improvement in calibration (intercept: 1.26). Our split-sample recalibration/validation approach 172 
demonstrated considerable improvement of predictive performances for most PCa-RCs 173 
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Discussion 180 
In this external validation study we comprehensively assessed all currently available mpMRI-PCa-RCs 181 
and compared them to two established mpMRI-naïve PCa-RCs. In general, the PCa-RCs incorporating 182 
mpMRI outperformed their mpMRI-naïve predecessors. Among all risk models under evaluation the 183 
mpMRI-PCa-RCs of van Leeuwen et al. and the mpMRI-ERSPC-RC showed a distinct clinical net 184 
benefit at a threshold of 15%. 185 
It has been shown that use of PCa-RCs can reduce overdiagnosis of clinically insignificant PCa at a 186 
small expense of missing csPCa compared to using a certain PSA-threshold for the decision to biopsy 187 
men. The use of such PCa-RCs in daily routine can be facilitated greatly by their online dissemination 188 
– as has been done for the ones based on the PSA-screening trials PCPT and ERSPC
12,22,23
. The PCa-RC 189 
of the Prostate Biopsy Collaborative Group (PBCG) is based on opportunistic screening cohorts and is 190 
propagated online as the quasi successor to the PCPT-RC
13
. Validation was performed with three 191 
large mpMRI-naïve European cohorts (n=10’377), but the PBCG-RC has not been independently 192 
validated so far. With performance of mpMRI becoming the de facto standard for patients at risk in 193 
many urological care centers and recent EAU guidelines approval
24
, radiological risk-assessment of 194 
csPCa is becoming increasingly available before prostate biopsy. Novel PCa-RCs incorporate mpMRI 195 
as an additional parameter, as the consequential next step to enhance their performance. Results 196 
from the PRECISION trial attest to the validity of mpMRI as a triage test for targeted biopsies in 197 
biopsy-naïve patients
5
. However, it does not address the risk of csPCa in men with negative mpMRI. 198 
The median negative predictive value (NPV) of mpMRI is 80.4 and 88.2% for biopsy-naïve patients 199 
and in a repeat biopsy setting, respectively, according to a recent meta-analysis
25
, but is strongly 200 
dependent on prevalence and therefore not generalizable. The current EAU guidelines put emphasis 201 
on clinical risk-assessment and shared decision making for how to proceed further with patients with 202 
negative mpMRI
24
. Wang and colleagues found individual risk assessment with PCPT-RC to correlate 203 
well with risk of csPCa in patients with negative mpMRI
26
, highlighting the potential role of PCa-RCs 204 
to select patients with low NPV of mpMRI who should receive biopsy notwithstanding
24
. If mpMRI is 205 
positive, individual risk assessment can strengthen the shared decision making process by conferring 206 
agency in well-informed patients
27
. Original reports of these mpMRI-PCa-RCs show encouraging 207 
discriminative performances (AUCs: 0.81-0.88)
6–9
 compared to the original reports of the mpMRI 208 
naïve ERSPC-RC and PBCG-RC (AUCs: 0.71-0.81)
12,13
. However, all risk models are dependent on 209 
multiple factors peculiar to their development cohorts, i.e. disease prevalence and biopsy method, 210 
hindering their direct generalizability. In line with this, validation studies of mpMRI-naïve PCa-RCs 211 
reported less optimistic results than expected from their original reports
10,28
. Of note, the mpMRI-212 
PCa-RCs of Mehralivand et al. and van Leeuwen et al. included an external validation in their original 213 
reports. Our study represents the first independent external validation study of mpMRI-PCa-RCs and 214 
their comparison to two established mpMRI-naïve PCa-RCs. In this effort we investigated all currently 215 
available mpMRI-PCa-RCs for csPCa to the best of our knowledge. 216 
The better discrimination of the PCa-RCs incorporating mpMRI can be simply explained by the 217 
additional information generated by the inherent diagnostic accuracy of the mpMRI
29
. The lower 218 
discriminative performance of the PBCG-RC (AUC: 0.69) might be further explained by its omission of 219 
prostate volume as a predictor. This hypothesis is in line with Ankerst and colleagues showing 220 
improved discrimination of the PCPT-RC by adding prostate volume as an additional predictor
30
. The 221 
hypothesis that the low discriminative performance of the PBCG-RC is caused by the high proportion 222 
of missing information on family history could not be confirmed in a sensitivity analysis. Differences 223 
of ethnical background between our cohort and some of the PBCG-RC’ development cohorts (i.e. the 224 
Durham cohort consisting of >60% men with African American ancestry) is another possible 225 
explanation for the underperformance
13
. 226 
The underprediction of the ERSPC-RC, PBCG-RC and mpMRI-ERSPC-RC is mainly driven by the lower 227 
prevalence of csPCa in their development cohorts of 4.5-35%. Among all risk models, the PCa-RC of 228 
Mehralivand et al. showed a prominent overprediction. Our hypothesis that the overestimation 229 
partly stems from the higher proportion of positive mpMRIs of 82.1% compared to 61.8% in our 230 
cohort was confirmed in a sensitivity analysis showing improved calibration after excluding patients 231 
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The minimal deviation in the calibration-in-the-large of the mpMRI-PCa-RCs from Radtke et al. and 233 
van Leeuwen et al. to our cohort could be explained by their systematic transperineal biopsy 234 
protocols with high coverage (median of 24 and 30 cores, respectively) similar to our approach 235 
(median of 40 systematic biopsy cores), compared to the 6-12 systematic cores biopsies used to the 236 
develop the other PCa-RCs. 237 
Combining discrimination, calibration and risk aversion in a clinical utility perspective, only the 238 
mpMRI-ERSPC-RC and the PCa-RC of van Leeuwen et al. demonstrated a distinct net benefit in our 239 
validation setting when a risk of a false-negative prediction of 15% is accepted. Application of the 240 
remaining PCa-RCs were even harmful in comparison to a biopsy all men strategy or manifested a 241 
clinical net benefit only at clinically implausible risk thresholds. 242 
The strength of our study is the comprehensive assessment (discrimination, calibration and clinical 243 
utility) of all currently available risk models for csPCa with mpMRI. Compared to other validation 244 
studies, we used a highly accurate gold standard for outcome ascertainment (transperineal 245 
saturation biopsy with a median of 40 systematic biopsy cores and fusion-guided targeted biopsy). 246 
Our study has limitations. Foremost, it is a retrospective study. A selection bias due to already 247 
previously performed risk assessments has to be considered. Furthermore, family history assessment 248 
was missing in 40%, which could have led to inferior performance of the PBCG-RC, although a 249 
sensitivity analysis (complete cases and multiple imputation analysis) showed no improvement. Since 250 
all our patients have Caucasian descent, our findings are not fully generalizable to more 251 
heterogeneous populations. 252 
Our results affirm the importance of choosing the best PCa-RC for a specific setting, which 253 
consequently warrants replication of our study in other centers with different screening, mpMRI and 254 
biopsy practices. In an idealistic setting, replication of our study in each Urologist’s own patient 255 
cohort would lead to the optimal choice. Although online dissemination of PCa-RC greatly facilitates 256 
their use in daily practice, risk models with unpublished regression coefficients hinder further much 257 
needed validation studies for different biopsy settings. Although recalibration led to expected 258 
predictive improvements for most PCa-RCs, this approach is usually not available in clinical practice 259 
and is not within the scope of this investigation. 260 
 261 
Conclusions 262 
In our external validation setting the best performances in regard to discrimination, calibration and 263 
clinical utility were achieved by PC-RCs incorporating mpMRI.  From a clinical utility perspective the 264 
mpMRI-PCa-RCs of van Leeuwen et al. and the mpMRI-ERSPC-RC outperformed the other models 265 
under evaluation. However, clinical net benefit could only be observed for non risk-averse men when 266 
a relatively high threshold range above 15% was applied. As clinical utility is strongly cohort 267 
dependent, but the use of certain PC-RCs facilitated greatly by its online dissemination, there is a 268 
strong need for more external validation for different biopsy settings. 269 
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Table 1 - Clinicopathological characteristics and biopsy results (n=468)
Variable missing values
    Age (years) 64.5 (59 - 68.9)
    PSA (ng/ml) 6.6 (4.5 - 9.9)
    Prostate volume (ml) 48.9 (36 - 63.7)
    Suspicous DRE 77 (16.5)
    Positive family history 50 (10.7) 190 (40.6%)
    Previous negative biopsy 145 (31)
Highest ROI (PIRADS version 2)





Systematic biopsy cores 40 (39-42)
Targeted biopsy cores per ROI 3 (2-3)
Biopsy results
   no PCa 220 (47)
   Gleason Score 6 55 (11.8)
   csPCa 193 (41.2)
Values represented as median with interquartile ranges or as number with percentage
of the whole cohort; DRE = digital rectal exam; ROI = region of interest; PCa = prostate cancer;
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Intercept: 1.74; Slope: 0.81
Intercept: −0.21; Slope: 0.65
Intercept: 0.42; Slope: 0.79
Intercept: −1.65; Slope: 1.1
Intercept: 1.1; Slope: 1.18
Intercept: 0.01; Slope: 0.61
mpMRI (Radtke et al.) mpMRI (Mehralivand et al.) mpMRI (van Leeuwen et al.)
ERSPC PBCG mpMRI (ERSPC)




























































mpMRI (Radtke et al.) 
mpMRI (Mehralivand et al.) 
mpMRI (van Leeuwen et al.)


























Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
